VC Fund Dossiers

a16z Crypto is the 800-pound gorilla of crypto VC with genuine conviction, not just FOMO money. They've stayed consistent through multiple crypto winters while others fled. The upside: massive network effects, regulatory connections, and they actually understand the technology. The downside: you're competing with their 150+ portfolio companies for attention, and their brand association might hurt if crypto sentiment sours. Chris Dixon is a true believer who will go to bat for you, but expect very high growth expectations given their fund size. They're surprisingly founder-friendly for such a big fund, but don't expect white glove treatment unless you're clearly a breakout company.

a16z crypto is the 800-pound gorilla that every other crypto VC both loves and fears. They have the deepest pockets, best brand, and Chris Dixon's Twitter following, but that comes with expectations of massive outcomes. They're genuinely helpful post-investment with intros, regulatory guidance, and platform support, but they're also not afraid to lead aggressive down rounds when markets turn. The regulatory expertise they built is real and valuable. Just know that taking their money means you're playing for unicorn-or-bust outcomes.

Bitkraft is probably the most credible gaming-focused VC out there, thanks to Jens Hilgers actually building ESL from scratch. They understand gaming culture and business models in ways that generalist VCs pretend to. The downside? They can be pretty narrow in their definition of what fits their thesis, and their portfolio skews heavily toward infrastructure and tools rather than actual game studios. If you're building gaming picks-and-shovels, they're gold. If you're making the next hit game, you might find them less helpful than you'd hope.

The OG crypto VCs who actually understand the technology and have the battle scars to prove it. Unlike funds that jumped into crypto during the 2021 hype cycle, these guys have been grinding since 2013 and have real conviction. They're genuinely helpful on tokenomics, regulatory strategy, and crypto-specific challenges that traditional VCs fumble. The downside? They can be overly crypto-maximalist and might push you toward token models when equity makes more sense. Also, their portfolio is so crypto-heavy that they're not great for companies that need traditional enterprise or consumer expertise.

CoinFund is one of the OG crypto VCs that actually understands the technology, not just the hype. Jake Brukhman can talk circles around most investors about protocol design, but that same depth sometimes means slower decision-making than newer crypto funds. They're genuinely helpful post-investment with technical guidance and crypto-native business model advice, though their network is more crypto-insider than mainstream tech. If you're building serious infrastructure or DeFi protocols, they get it. If you need help crossing the chasm to mainstream adoption, their traditional tech experience via Pakman helps, but you might want additional mainstream VCs on your cap table.

DCG is crypto royalty with the receipts to prove it - they backed Coinbase, Circle, and basically every name that matters. But here's the thing: Barry Silbert just survived a nuclear winter that would have killed most funds. The NY AG sued them for allegedly defrauding 230,000+ investors of $1.1B, Genesis went bankrupt owing billions, and Gemini's Cameron Winklevoss publicly called Silbert a fraud on Twitter. Yet somehow DCG posted 51% revenue growth in 2024 and paid back $4B to Genesis creditors. Now Silbert's doubling down on decentralized AI with his new Yuma subsidiary - the guy clearly doesn't do small bets. The question is whether you want a battle-tested survivor who's seen every crypto apocalypse, or if all that legal drama makes you nervous.

Dragonfly is what happens when you get the formula right: contrarian timing, genuine technical depth, and partners who actually complement each other's skills. They've historically raised during downturns and called it a 'mass extinction event' for competitors while closing $650M - that's not luck, that's discipline. Their Fund III bets on Polymarket, Ethena, and Rain catapulted them into competition with a16z and Paradigm. The DOJ drama over Tornado Cash actually earned them street cred with crypto natives. What founders need to know: they want to know if you can bring them into rooms where their words carry weight, and they expect you to truly help move things forward beyond just capital. They conduct deep technical diligence and provide active support beyond capital. The public Twitter drama between Qureshi and Pack shows they don't shy away from messy situations, which can be good or bad depending on your tolerance for founder theatrics.

Entrée is what happens when actual operators build a VC fund - and it shows in their portfolio performance. With offices in Israel, UK, and the US, Entrée Capital has realized 30 exits and IPOs and its portfolio has 18 unicorns. Avi Eyal's track record speaks for itself: he's the guy who led monday.com from seed to $8B+ IPO and got Amazon to pay hundreds of millions for PillPack. Unlike many VCs who just write checks, this team actually helps founders build companies - they have operational DNA from being serial entrepreneurs themselves. The downside? They can be picky to the point of being almost arrogant about what constitutes "exceptional" founders, and their Israeli roots mean they have strong opinions about how things should be done.

F-Prime is what happens when you take Fidelity's $2 trillion checkbook and 50+ years of VC experience and point it at early-stage companies - they're one of the few funds that actually creates companies from scratch (30+ times) rather than just writing checks to existing startups. "I have seen the F-Prime team at work from the perspective of a founder and as a venture partner," Eric told us. "They have a massive wealth of knowledge and supportive resources at their disposal. If they aren't able to help portfolio companies with a problem, they almost certainly know someone who can — and they're always happy to make the introduction." The "technical-risk-yes, regulatory-risk-no" filter is smart - they'll back CRISPR but avoid antibiotics. Their healthcare track record is legitimately impressive (Toast, Flywire, Beam, Denali), and having no external LPs means they can be patient capital when others are panicking. Stephen Knight has been there 20+ years and knows what he's doing.